Creative Commons source reading · Neurosurgical oncology
Agents for fluorescence-guided glioma surgery: a systematic review of preclinical and clinical results.
Joeky T Senders; Ivo S Muskens; Rosalie Schnoor; Aditya V Karhade; David J Cote; Timothy R Smith; Marike L D Broekman
Originally published in Acta neurochirurgica · 2016-11-22
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background Fluorescence-guided surgery (FGS) is a technique used to enhance visualization of tumor margins in order to increase the extent of tumor resection in glioma surgery. In this paper, we systematically review all clinically tested fluorescent agents for application in FGS for glioma and all preclinically tested agents with the potential for FGS for glioma. Methods We searched the PubMed and Embase databases for all potentially relevant studies through March 2016. We assessed fluorescent agents by the following outcomes: rate of gross total resection (GTR), overall and progression-free survival, sensitivity and specificity in discriminating tumor and healthy brain tissue, tumor-to-normal ratio of fluorescent signal, and incidence of adverse events. Results The search strategy resulted in 2155 articles that were screened by titles and abstracts.
Results
We identified 2155 studies in PubMed and Embase after duplicates were removed. After screening by title and abstract, 237 studies remained for full-text review. Of these, we included 105 studies describing the use of clinically or pre-clinically tested fluorescent agents for application in FGS for glioma (Fig. 1). Detailed characteristics of all 105 studies included in this review are available in Table 2. Three studies were randomized clinical trials, of which two had partially the same data set. Three studies were meta-analyses.
Discussion
Various fluorescent agents have been studied for use in glioma surgery, of which 5-ALA, ICG, fluorescein, hypericin, AFL-HSA, and endogenous spectroscopy have been tested clinically (Table 3).
Conclusions
In FGS for glioma, fluorescent agents should be easy to apply, safe to use, and tumor-specific. The fluorescent signal should be strong and easy to detect. Currently, 5-ALA is the only agent that has been tested in a multi-center RCT and has been approved for clinical use in certain parts of the world. Other clinically tested exogenous agents for FGS for glioma include fluorescein, ICG, AFL-HSA, and hypericin. Despite their contributions to GTR, due to their non-specific mechanism of action, preclinical research has shifted away from these products and towards molecular targeting (e.g., anti-EGFR).
Editorial reading guide
- How were patients or cases selected, and what did the authors use as a comparator?
- Which outcomes, complications and follow-up intervals determine how far the findings apply?
